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melanocortin 2 receptor  (MC2R) gene in this patient.  Re-
sults: We report on a 3-month-old boy with familial gluco-
corticoid deficiency who presented at the age of 3 months 
with skin hyperpigmentation, muscle weakness, mild jaun-
dice and constipation. Hormonal analyses revealed high 
ACTH and TSH serum concentrations, low serum cortisol 
concentration along with normal blood electrolytes. On hy-
drocortisone supplementation, the disease symptoms dis-
appeared and the child recovered completely. His physical 
and mental development progresses normally. Genetic anal-
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 Abstract 
 Objective: Description of the clinical, biochemical and ge-
netic features of a Polish patient with familial glucocorticoid 
deficiency.  Methods: Detailed clinical investigation, hor-
monal analysis and sequencing of the coding region of the 
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 Established Facts 
 • Familial glucocorticoid deficiency (FGD) is a rare, genetically heterogeneous, autosomal-recessive 
disease characterized by ACTH-resistant adrenal failure. 
 • About 25% of the patients carry mutations in the melanocortin 2 receptor gene (MC2R, FGD type 1) 
and 20% mutations in the melanocortin 2 receptor accessory protein gene (MRAP, FGD type 2), 
whereas more than 50% of the patients lack mutations in both genes. 
 Novel Insights 
 • Prolonged jaundice, constipation, profound skin hyperpigmentation and muscular hypotonia can be 
the first signs of the disease. 
 • The novel p.Leu46fs mutation is the first frameshift mutation within the first transmembrane domain 
of the melanocortin 2 receptor (MC2R). 
 • The novel p.Val49Met mutation is at the junction of the first transmembrane domain to the first in-
tracellular loop. The affected amino acid valine 49 is highly conserved between different species and 
molecular modeling revealed that the substitution of valine 49 by methionine results in the recruit-
ment of 48Ala and 49Met into the alpha helix of the first transmembrane domain (TMD) of the ACTH 
receptor which consecutively enables an interaction between 49Met and 273Pro (TMD VII). 
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ysis disclosed a novel compound heterozygous  MC2R muta-
tion p.Leu46fs and p.Val49Met.  Conclusion: The heterozy-
gous p.Leu46fs mutation adds to the small number of  MC2R 
nonsense mutations and is the first frameshift mutation 
within the first transmembrane domain of the receptor.
According to molecular modeling the Val49Met mutation
results in a structural change of the first transmembrane
domain and in a potential novel interaction of the trans-
membrane domains I and VII.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Familial glucocorticoid deficiency (FGD) is a rare au-
tosomal-recessive disorder, which was first described by 
Shepard et al. [1] in 1959. The disorder belongs to a group 
of diseases associated with ACTH-resistant adrenal fail-
ure. FGD is synonymously named isolated glucocorticoid 
deficiency or hereditary unresponsiveness to ACTH. 
FGD is genetically heterogeneous in that only 25% of the 
patients carry mutations in the melanocortin 2 receptor 
(ACTH receptor) gene  (MC2R)  [2–6] . These patients were 
classified as having FGD type 1. It has recently been 
shown that 20% of all FGD cases bear mutations in the 
gene for melanocortin 2 receptor accessory protein 
 (MRAP)  [7] . FGD type 1 and type 2 patients show no sig-
nificant phenotypic differences  [6, 7] . More than 50% of 
the patients lack mutations in both genes,  MC2R and 
 MRAP  [5] , and at least one further gene locus on chromo-
some 8q12.1-q21.2 has been identified  [8] . Here we report 
on a patient with FGD due to a novel compound hetero-
zygous  MC2R  mutation.
 Case Report 
 A male infant, born at 38 weeks of gestation [birth weight 
3,850 g (50th percentile), length 54 cm (90th percentile)] was ad-
mitted to the hospital at the age of 3 months because of prolonged 
jaundice (total bilirubin level 20.7 mmol/l, normal range (NR) 
1.7–20.7 mmol/l) and constipation. On admission, the child pre-
sented with profound skin hyperpigmentation and muscular hy-
potonia the latter being present since the postnatal period. Liver 
enzyme levels (alanine aminotransferase, aspartate aminotrans-
ferase, gamma-glutamyl-transpeptidase) remained within nor-
mal ranges. Ultrasound of liver and biliary ducts did not show any 
pathology. Blood cell count, hemoglobin concentration and 
erythrocyte osmotic resistance were normal. Thyrotropin (TSH) 
level was elevated with 13.9 mU/l (NR 0.62–8.05 mU/l), whereas 
thyroid hormones were within reference values. Although the bil-
irubin level normalized and constipation disappeared after 10 
days of hospitalization, muscle weakness and skin hyperpigmen-
tation persisted. At cerebral ultrasound examination and mag-
netic resonance (MR) scans of the brain no structural abnormal-
ities were found to be responsible for the observed muscular hy-
potonia. Hormonal analysis revealed low levels of cortisol 
throughout the day (8 a.m. 10.9 nmol/l, 2 p.m. 17.2 nmol/l and 10 
p.m. 11.4 nmol/l; NR morning cortisol 165.5–786.3 nmol/l, NR 
afternoon cortisol 110.3–413.8 nmol/l). ACTH level was  1 1,275 
pmol/l (NR  ! 10 pmol/l). A high prolactin (PRL) level of 20   g/l 
(NR 3.9–20.1   g/l) was found, while serum 17-hydroxyprogester-
one and plasma renin concentrations were within the normal 
ranges. A 24-hour urine steroid excretion examination was per-
formed twice and revealed a complete lack of cortisol excretion 
with normal excretion of mineralocorticoids and androgens. At 
abdominal ultrasound, the adrenal glands appeared hypoplastic. 
During the time of hospitalization, no water-electrolyte distur-
bances or hypoglycemic episodes were observed. ACTH levels in 
the parents of the index patient were within normal ranges. In the 
clinically healthy 6-year-old sister the ACTH level was slightly 
elevated (13.9 pmol/l, NR  ! 10 pmol/l), whereas the 24-hour urine 
steroid profile was normal.
 With gas chromatography mass spectrometry (GCMS), we re-
vealed normal organic and amino acid levels excluding organo-
acidopathies and disturbances in amino acid metabolism. Nor-
mal values of very-long-chain fatty acids (VLCFA) excluded ad-
renoleukodystrophy as a cause for the adrenal failure of the child. 
The patient showed a normal male 46,XY karyotype. Initially, the 
patient was commenced on 30 mg/m 2 /day hydrocortisone and 
subsequently, on a maintenance dose of 15–20 mg/m 2 /day. On 
treatment, the general state of the child improved quickly, muscle 
tonus normalized, and skin hyperpigmentation gradually disap-
peared. Throughout the observation period (18 months) his body 
weight and height remained within the normal values for age and 
parents height (father 186 cm, mother 168 cm). At the chrono-
logical age of 21 months his bone age was differentially delayed by 
between 3 months (carpal bones) and 18 months (metacarpals 
and finger bones). After 4 months of hydrocortisone treatment 
the ACTH level gradually decreased to 18.7 pmol/l. At regular fol-
low-up investigations electrolytes, glucose concentration, and ar-
terial blood pressure remained normal. Under  L -thyroxine sub-
stitution TSH levels normalized within 1 week and remained nor-
mal during the time of therapy. After 3 months  L -thyroxine 
treatment was stopped, and during a 1.5-year follow-up period 
TSH and free thyroxine (fT4) levels remained within normal 
ranges.
 Molecular Genetic Results 
 Mutation analysis of the  DAX1 gene revealed no ab-
normality thus excluding congenital adrenal hypoplasia. 
Based on the clinical picture and hormonal levels, the 
 diagnosis of FGD was proposed. Sequencing analysis of 
the  MC2R gene revealed a compound heterozygous mu-
tation combining two novel mutations: a G 1 A transition 
c.145G 1 A resulting in a missense mutation (p.Val49Met) 
on one allele and a single nucleic acid deletion (c.137delT) 
resulting in a frameshift after Leucin 46 (p.Leu46fs). As 
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expected, the parents are heterozygous carriers of the 
 disease in that the father harbors the heterozygous p.Val-
39Met mutation, and the mother and healthy sister of the 
patients carry the heterozygous c.137delT deletion ( fig. 1 ). 
The p.Leu46fs and p.Val49M mutations have not been 
found in 60 unrelated healthy control subjects.
 Molecular Modeling of the Val49Met Mutation 
 The MC2 receptor belongs to the G-protein coupled 
receptors (GPCR). This large group of proteins share sev-
en transmembrane domains (TMD) as their common 
structural denominator. As only a 3D structure exists for 
bovine rhodopsin (PDB: 1HZX), other GPCRs can be 
modeled according to a rule-based technique  [9] taking 
into account multiple sequence alignments of a certain 
subfamily of receptors, and the clear determination of the 
trans-membrane regions. As no experimental evidence 
exists for the structure of the loops that connect the heli-
ces, no inference can be made about these. The position 
of the TMDs of the MC2R was taken from the GPCR-da-
tabase (GPCRDB, http://www.gpcr.org/7tm). The TMDs 
are depicted in a 2D snake diagram ( fig. 2 a)  [10] . The 3D 
structure of the seven TMDs was modeled with the pub-
licly available GPCR software in (SWISS-MODEL, http://
swissmodel.expasy.org) and the graphic output was gen-
erated with SWISS DeepView v3.7 and rendered with the 
public domain software POVRAY. The mutated 49Val at 
the C-terminus of the first TMD is not part of the alpha-
helix which ends at 47Leu. In the presence of the Val-
49Met mutation, both 48Ala and 49Met are recruited into 
the alpha-helix of TMD I ( fig. 2 d, e), possibly distorting 
the original structure. Additionally the methyl-groups of 
49Met and 273Pro (TMD VII) may come into close prox-
imity (5.1 Å) thus enabling hydrophobic interaction be-
tween them. Potential interactions of 49Met with the first 
intracellular loop (AA48–58) cannot be inferred. In con-
trast, the alpha-helix of TMD I is not changed with the 
known Val45Ile polymorphism ( fig. 2 f, g).
 Discussion 
 Patients with FGD usually present with an isolated 
glucocorticoid production defect. Very high ACTH levels 
in the presence of low cortisol levels indicate a defect of 
ACTH signaling either at the ACTH receptor level or in 
the signal transduction system.
 Many cases of FGD type 1 have been associated with 
mutations in the  MC2R gene, and these mutations have 
been shown to segregate with the disease in affected fam-
ilies  [5] . In our index patient we identified two novel het-
erozygous mutations in the melanocortin 2 receptor 
which lie within the first transmembrane domain (TMD 
I) and at the junction of the TMD I to the first intracel-
Father
Val49Met heterozygous
Mother
Leu46fs heterozygous
Sister
Leu46fs heterozygous 
Patient
Leu46fs heterozygous and 
Val49Met heterozygous
c.137delT c.145G>A
Control
 Fig. 1.  MC2R mutations in the index pa-
tient with FGD and his family. Sequence 
chromatograms of the patient, his healthy 
parents and sister in comparison with the 
respective wild-type (control) sequence. 
Only in sequence chromatograms of the 
reverse reaction is the G 1 A mutation visi-
ble in the patient due to the adjacent frame-
shift mutation. The arrow indicates the nu-
cleotide altered by the mutation that oc-
curred at c.137delT and c.145G 1 A. The 
nomenclature is in accordance to den Dun-
nen (http://www.hgvs.org/mutnomen/). 
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lular loop of the receptor. The 1-bp deletion c.137delT re-
sults in a shift of the open reading frame after Leu46 fol-
lowed by a premature stop codon after 37 amino acids. It 
can be assumed that this markedly truncated protein will 
be functionless. Most of the mutations described so far 
are missense mutations. This heterozygous p.Leu46fs 
mutation adds to the small number of nonsense muta-
tions and is the first frameshift mutation within the first 
transmembrane domain of the MC2R. The second muta-
tion p.Val49Met results in an exchange of a hydrophobic 
nonpolar amino acid valine by the sulfur-containing hy-
drophobic non-polar amino acid methionine. The func-
tional relevance of the second mutation can only be in-
ferred from molecular modeling. The distortion of the 
C-terminus of the first TMD and of the first intracellular 
loop may result in a loss of signal transduction rather 
than a structural disruption or impairment of ligand 
binding on the extracellular surface. The adjacent natu-
rally occurring mutation p.Ile44Met results in a near loss 
of signal transduction but shows virtually normal bind-
ing parameters  [11] . On the other hand, the p.Val45Ile 
mutation, found as a heterozygous mutation in one FGD 
patient with a normal second allele, did not significantly 
alter the signal transduction pathway and was assumed 
to be a polymorphism  [12] . This can be confirmed by mo-
lecular modeling in that the alpha-helix of TMD I is not 
changed with the Val45Ile polymorphism.
 The different functional relevance of the p.Ile44Met 
and the p.Val45Ile mutations demonstrates that each 
amino acid must have its unique role for ACTH receptor 
function, and we assume that the Val49Met at the junc-
tion of the first transmembrane domain to the first intra-
cellular loop will probably be a disease-causing mutation. 
Moreover, the valine 49 is highly conserved between dif-
ferent species ( fig. 3 ), the mutation has not been found in 
60 unrelated healthy control subjects and the mutation 
segregates with the disease in the family suggesting that 
this residue might have an important role for MC2R func-
tion.
 In the past, poor correlation between gene defect and 
clinical phenotype was observed. Even in patients carry-
ing identical  MC2R mutations, differences in phenotype 
exist  [11] . Moreover, a poor correlation between severity 
of receptor dysfunction determined in vitro and the age 
of onset of the symptoms as well as disease severity and 
plasma cortisol levels was reported  [3, 7, 13] . Some pa-
tients with FGD type 1 have been described to be unusu-
ally tall  [11, 14] . The measurements of human growth 
hormone and insulin-like growth factor (IGF-1) in these 
patients remained normal  [3] . Tall stature and advanced 
bone age were described in patients with FGD, but not all 
the patients with the same  MC2R mutation presented 
with tall stature. It is suspected that the advanced bone 
age and growth may be due to high levels of ACTH and 
its action on MSH receptors in bone cartilage, as well as 
estradiol synthesis stimulation with a consecutive influ-
ence on bone tissue. Anabolic action of growth hormone 
without the catabolic cortisol influence could be another 
explanation  [15, 16] . Our patient presented with a normal 
growth rate slightly above the 50th percentile with an ab-
49Val
wild type
a
b c f
273Pro 273Pro
279
259242
218
181166
197148
140
126
61
80
100
Met
24
47
49
45lle
5.1 Á49Met49Val
45Val
ed g
49Val
mutant
Val45lle
polymorphism
 Fig. 2.  a 2D snake diagram of the MC2 receptor taken from 
GCPRDB. The Val49Met mutation is located in junction zone be-
tween the first TMD and the first intracellular loop. Known mu-
tations are depicted in white.  b ,  c No gross distortion of the seven 
TMDs can be seen in the presence the mutation (49Met). The dot-
ted boxes are zoomed in the lower panel.  d ,  e Close inspection of 
the C-terminus of the first TMD reveals the alpha-helix of to be 
enlarged by two amino acids in the presence of the Val49Met mu-
tation (arrow). Additionally, the methyl-groups of 49Met and 
273Pro come into close contact thus enabling hydrophobic inter-
action.  f, g No change of the alpha-helix is seen in the presence of 
the Val45Ile mutation. 
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solute height within the midparental range. However, his 
bone age was found to be dissociated and retarded.
 The incidence of FGD in the general population is not 
known. It is a rare disease and more than 50 cases have 
been reported so far  [5] . However, the FGD incidence 
could be underestimated because some patients may be 
misdiagnosed as having just recurrent infections or sei-
zures. A misinterpretation of these symptoms may be fa-
tal for the patient as hypoglycemic shock followed by ce-
rebral damage or death has repeatedly been reported in 
FGD families.
 In our patient, skin hyperpigmentation as well as mus-
cle weakness were present from birth. The prolonged 
jaundice points to the clinically relevant cortisol defi-
ciency as it can be seen in patients with neonatal hypopi-
tuitarism  [17, 18] . It was proposed that cortisol can influ-
ence bile formation, and a reduction of bile flow has been 
observed in adrenalectomized rats  [19] . In fact, cholesta-
sis and neonatal hepatitis has been described as a leading 
symptom in isolated glucocorticoid deficiency  [20] .
 Our patient presented with an elevated TSH concen-
tration at the age of 3 months with normal levels of pe-
ripheral thyroid hormones. In order to prevent any hypo-
thyroid episode in early infancy, we started treatment 
with a low dose of  L -thyroxine. The reason for the TSH 
elevation remains uncertain, although within the first 
year of life the TRH-TSH axis can be activated which may 
result in high TSH levels despite peripheral euthyroid-
ism. As thyroid ultrasound was normal in our patient, we 
stopped thyroxine treatment, and re-evaluation of thy-
roid function revealed normal results in a 1.5-year follow-
up. This case is obviously different from the observation 
of Tiosano et al. who described a large consanguineous 
kindred with FGD and profound hypothyroidism, the 
latter being due to a novel point mutation in the thyrotro-
pin receptor leading to TSH resistance  [21] . In this fam-
ily, the presence of hypothyroidism did not affect the tim-
ing, severity and manner of the isolated glucocorticoid 
deficiency.
 The treatment of FGD consists of glucocorticoid sub-
stitution therapy, which helps re-establish normal metab-
olism as well as normal growth  [15] . Typical oral hydro-
cortisone doses are 12–15 mg/m 2 /day. Clinical signs of 
effective FGD treatment are: normal height and weight 
gain, reduction of the frequency of severe infections, and 
normal glucose concentration in blood. In our patient, we 
had to start with an initial dose of 30 mg/m 2 /day, then 
lowered the dose to 15–20 mg/m 2 /day. On this treatment, 
ACTH levels returned to normal, which is not always the 
case in FGD patients  [22] .
 As in other glucocorticoid-treated patients, growth 
and development of the children should be carefully 
monitored, and the hydrocortisone dose needs to be ap-
propriately increased in times of fever, stress and surgery. 
No mineralocorticoid treatment is required. Twenty four-
hour ambulatory medical aid should be easily accessible 
to those patients in case of emergency. Frequent outpa-
tient clinic visits are essential to establish and maintain 
                                                         *  *
HUMAN       MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMY 
BOVIN       MKHILNLYENINSTARNNSDCPAVILPEEIFFTVSIVGVLENLMVLLAVAKNKSLQSPMY
PIG         MKHITDLYESVNSTMSNKSDCPPVVLPEEVFFTISVIGVLENLIVLLAVIKNKNLQSPMY
ELEMA       MKHIINPYENINNSARNNSDCPPVVLPEEIFFTISIVGVLENLIVLLAVIKNKNLQSPMY
SHEEP       MRHILNLYENINSTARNNSDCPAVILPEEIFFTVSIVGVLENLMVLLAVAKNKSLQSPMY
MOUSE       MKHIINSYEHTNDTARNNSDCPDVVLPEEIFFTISVIGILENLIVLLAVIKNKNLQSPMY
CAVPO       MKHIIHASGNVNGTARNNSDCPHVALPEEIFFIISITGVLENLIIILAVIKNKNLQFPMY
MESAU       MKHIITPYEHTNDTARNNSDCPDVVLPEEIFFTISIIGVLENLIVLLAVVKNKNLQCPMY
CHICK           IPSLENITDFSLNITDCNQVVVPEEVFFTVAAAGILENLLVLVAVIRNKNLHLPMY
BRARE HTDCAEVQVPGQVFLVIAVASLSENLLVIVAVIKNKNLHSPMY
TETNI MNATTVNRSDCPEVNVPIHIFFTIGFVSLAENLLVIVAIFWNRNLHSPMY
TAKRU MNATTVNRSDCPEVNVPIHVFFTIGFVSLLENLLVIGAISWNRNLHSPMY
 Fig. 3. Homology comparison of the first 60 amino acids of MC2R protein sequence from 
twelve different species (human:  Homo sapiens AAI04171, bovine:  Bos taurus P34974, 
pig:  Sus scrofa Q8HYN8, elema:  Elephans maximus ABG37017, ovine:  Ovis aries Q9TU77, 
mouse:  Mus musculus Q64326, cavpo:  Cavia porcellus Q9Z1S9, mesau:  Mesocricetus au-
ratus P70115, chick:  Gallus gallus NP_001026686, brare:  Danio rerio AAO24743, tetni: 
 Tetraodon nigroviridis AAQ55177, takru:  Takifugu rubripes AAO65550). Amino acids 
which are different in comparison with the human sequence are highlighted in gray, 
conservative substitutions are indicated with bold letters. The amino acids L46 and V49 
are indicated with an asterisk. 
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the treatment with the lowest possible dose of steroids. 
We recommend to offer genetic counseling to the affect-
ed families.
 Methods 
 Blood samples were taken from the family after ob-
taining written informed consent. Primer sequences and 
PCR conditions used for amplification of exon 2 of the 
 MC2R gene are available upon request. For sequencing, 
PCR products were purified with the QIAquick PCR Pu-
rification Kit (Qiagen, Hilden, Germany). The sequenc-
ing was performed with an ABI 3100 Genetic Analyzer 
(Applied Biosystems, Foster City, Calif., USA) using the 
Big Dye Terminator v 1.1 Cycle Sequencing kit (Applied 
Biosystems). Base calling was done with the DNA Se-
quencing Analysis Software, version 3.7 (Applied Biosys-
tems) and sequences were aligned and analyzed with the 
Sequence Navigator software, version 1.0.1 (Applied Bio-
systems). In 60 healthy control individuals, we sequenced 
nucleotides 1–271 (amino acid 1–90) and did not find se-
quence abnormalities at amino acid positions L46 and 
V49.
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